LAUSR

IntroductionCurrent health trends indicate that the rate of incidence of obesity has risen considerably. According to the World Health Organization (WHO) report 2017, the issues of obesity has grown to epidemic proportion, with over 4 million people dying every year. Orlistat, a potent pancreatic lipase (PL) inhibitor for long-term treatment of obesity has been recently reported to cause hepatic and renal toxicities. Hence, there is a need to develop newer, safer and efficacious therapeutics that targets obesity and its associated disorders. Research groups around the globe are working towards the discovery of natural origin-based compositions as a valid alternative for obesity treatment.Areas coveredThe present article attempts to review patents of compositions of natural origin that includes either combination of two or more lead NPs/whole extract(s)/ mixture of one or more NPs/extracts from various plants and micro-organisms. Patents that were granted during the period 2010 to 2021 are being considered.Expert opinionThe article highlights the recent trends in the rise of global obesity population along with its pathogenesis. Patents are classified based on the mechanism of action of extracts/NPs. It has been observed that to protect the Intellectual Property Right (IPR) of the original research, the tendency of patent filing for the anti-obesity compositions has increased.